At the Pacific Coast Reproductive Society's annual meeting, Kristin Brogaard, our co-founder and Chief Scientific Officer, was honored with the "2024 Outstanding Paper - 2nd Place" for her presentation on NOA Guide, a non-invasive test developed to predict the success of sperm retrieval in mTESE procedures for men with non-obstructive azoospermia. This innovative approach aims to reduce the physical and emotional strain of unsuccessful treatments, marking a significant advance in reproductive health.

This collaboration is set to advance male reproductive health by integrating Inherent Biosciences’ Epigenetic Sperm Quality Test (SpermQT^TM) into Genomic Prediction’s robust suite of clinical laboratory tests.

Inherent Biosciences is one of the first recipients of the Utah Innovation Fund's investment. This groundbreaking initiative by the state of Utah is a monumental step towards supporting deep tech startups, demonstrating a strong commitment to the entrepreneurial spirit and innovation.

At the ASRM 2023 conference, Inherent Biosciences presented groundbreaking male fertility research, heralding new possibilities in reproductive medicine. Read how Inherent Biosciences is leading the way.

Inherent Biosciences’ Sperm Quality Test (SpermQT) now published in Fertility & Sterility Science - the premier journal publishing peer-reviewed original scientific articles in basic, laboratory, and translational research that has strong potential to transform clinical practice.

AUA 2023 Best Posters: Epigenetic-based Test to Accurately Predict Successful Microscopic Testicular Sperm Extraction Outcomes

Our CEO, Andy Olson, sat down with Mark Tullis of TechBuzz to share the significance of the $1.9M SBIR Fast-Track grant and how we will use it to further our mission of raising the standard of care in reproductive health.

We secured a $1.9M Fast-Track grant from the National Institutes of Health (NIH) to advance our mission in reproductive health. Our commitment to innovation is unwavering, and this grant is a testament to the transformative potential of our research in assisted reproductive technologies.

We are thrilled to announce that our latest research paper, "Tissue-specific DNA methylation variability and its potential clinical value," has been published in the esteemed journal, Frontiers in Genetics. This publication is a testament to our commitment to advancing the understanding of complex diseases through innovative research.

HealthTech Investors announced Inherent Biosciences is the winner of their inaugural pitch competition!

“Andy Olson and Kristin Brogaard, PhD have built something special at Inherent Biosciences. We are impressed by their fortitude, perseverance and the diligent approach they have taken. Very excited to continue working with them!” - Rishad Usmani, MD

Inherent Biosciences’ products and technology were on display in multiple clinical and scientific presentations at the AUA 2023 annual meeting. Clinical and academic collaborators presented progress in the assessment of male infertility and prediction of treatment success for patients suffering from male infertility.

American Society of Andrology Annual Meeting 2023

Inherent Biosciences in collaboration with Seattle Sperm Bank presented the possibility of using SpermQT to qualify more sperm donor samples for use with intrauterine insemination (IUI) procedures.

Reproductive Health Innovation Summit

“Of all infertility cases, approximately 40-50% is due to a “male factor” infertility. Where are the latest innovations in male infertility and how can we spur these on to balance the scales, ensuring that men are receiving sufficient treatment? How can we build on this opportunity to reduce the stigma surrounding men’s healthcare? And what will the knock-on impact be for women’s health?”

- Women’s Health Innovation Series

Partnership enables Inherent to offer its Path Fertility branded Sperm Quality Test (SpermQT^TM) directly to consumers

SpermQT is a new epigenetic sperm quality test that looks inside the head of the sperm to examine gene function

We sat down with Amelia England of Tech Buzz to share how we are pioneering Epigenetic medicine to radically transform how we diagnose and treat complex diseases like infertility.

After analysis of over 1300 semen samples, we introduce the discovery of an epigenetic biomarker that is predictive of sperm quality that when combined with the semen analysis support better treatment guidance and precision fertility care.

Inherent seeks to redefine the path to parenthood by raising the standard of male reproductive health through the commercialization of an Epigenetic Sperm Quality Test (Path SpermQT).

New technology and diagnostics are needed for better assessment of male infertility. The mainstay of male factor infertility diagnosis is the standard semen analysis (sperm concentration, motility, and morphology) has changed very little over the last several decades and has been shown to have limited value. Here we complete a prospective analysis of men seeking fertility care using a newly available epigenetic sperm quality test (SpermQT).

NOA is present in 10-15% of infertile men where no sperm are present in the ejaculate due to failure of sperm production (spermatogenesis). Thus, this Small Business Innovation Research (SBIR) project focuses on an intractable clinical problem for specialists in reproductive medicine seeking to treat severe male factor infertility due to NOA. Importantly, there is increasing evidence to show that certain causes of male infertility may be associated with an increased risk of serious health conditions.

SpermQT analyzes epigenetic patterns (DNA methylation) on genes associated with sperm production, sperm maturation, and embryo development. The test was validated with data from over 2,000 semen samples showing a sensitivity of 84% in predicting the need for In Vitro Fertilization (IVF) treatment. A detailed white paper describing the development and validation of SpermQT is available for download at pathfertility.com. A manuscript is in preparation for peer reviewed publication.